These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33460667)

  • 21. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
    Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E
    Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E; Bryzinski B; Hirshberg B; Cook W
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
    Fang H; Xu F; Du J; Liang L; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
    J Diabetes Investig; 2020 Jul; 11(4):896-905. PubMed ID: 32020731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
    Kadowaki T; Muto S; Ouchi Y; Shimazaki R; Seino Y
    Expert Opin Pharmacother; 2017 Dec; 18(18):1903-1919. PubMed ID: 28901796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
    Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
    J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
    Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
    Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
    Gu W; Liang L; Wang S; Wang Y; Wu Y; Tian J; Yang G; Piao C; Li Y; Yin J; Xin X; Tan X; Ning G; Wang W;
    J Diabetes; 2016 Nov; 8(6):809-815. PubMed ID: 26676908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
    Hollander PL; Li J; Frederich R; Allen E; Chen R;
    Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
    Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
    Melzer Cohen C; Davis C; Shalev V; Chodick G
    J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Tahrani AA; Piya MK; Barnett AH
    Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
    Fofonka A; Ribeiro JP; Casali KR; Schaan BD
    Trials; 2014 Nov; 15():424. PubMed ID: 25366037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
    Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
    Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
    Zhuang Y; Song J; Ying M; Li M
    Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.
    Leibowitz G; Cahn A; Bhatt DL; Hirshberg B; Mosenzon O; Wei C; Jermendy G; Sheu WH; Sendon JL; Im K; Braunwald E; Scirica BM; Raz I
    Diabetes Obes Metab; 2015 May; 17(5):487-94. PubMed ID: 25656169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.